Clene Inc (Nasdaq:CLNN), a clinical-stage biotechnology company focused on amyotrophic lateral sclerosis (ALS), announced on Monday the closing of a registered direct offering of common stock to existing shareholders, including insiders, with total gross proceeds of USD4m.

The offering was led by Clene's chairman of the board of directors, David Matlin, alongside founding investor Kensington Capital Holdings, Clene's chief executive officer and other existing shareholders.

The company says that the offering was made without a placement agent, underwriter, broker or dealer, and is expected to provide Clene with sufficient cash to fund its operations to mid-first quarter 2027, which is beyond the potential US Food and Drug Administration (FDA) decision for accepting the New Drug Application (NDA) for review of CNM-Au8 for treatment of ALS under the accelerated approval pathway. In addition, if the FDA accepts the NDA from Clene for review, the company could potentially receive USD6.7m to USD7.8m in proceeds from common stock warrants issued in a January 2026 financing that could further extend the company's cash runway.